Jade Cury-Martins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jade Cury-Martins has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
- José Antonio Sanches
Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil
18 shared publications - Denis Miyashiro
Department of Dermatology University of São Paulo Medical School Sao Paulo Brazil
12 shared publications - Juliana Pereira
Faculdade de Medicina da Universidade de São Paulo
5 shared publications - Adriana Pessoa Mendes Eris
Dermatology Clinic, Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil; Skin Cancer Unit, A.C. Camargo Cancer Center, São Paulo, SP, Brazil
2 shared publications Alberto J.S. Duarte
Medical Investigation Laboratory (LIM-56), Tropical Medicine Institute of São Paulo, Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil
2 shared publications- Austin Hamp
Arizona College of Osteopathic Medicine Midwestern University Glendale, AZ United States
2 shared publications
Latest Publications
- Open Access
- 18 December 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (2) , 304-308
Immunoprofiling Reveals GATA3 as a Prognostic Marker in Transformed Mycosis Fungoides
Transformed mycosis fungoides (TMF) is a rare, aggressive variant of cutaneous T‐cell lymphoma characterized by the presence of large neoplastic cells and poor clinical outcomes. A retrospective cohort of 22 TMF patients was analyzed using immunohistochemistry on formalin‐fixed, paraffin‐embedded (FFPE) tissue for GATA3 ( n = 20), T‐bet ( n = 22), and STAT3 ( n = 22). Expression was quantified by image analysis integrated optical density per total area (IOD/area), standardized by z ‐score and correlated with survival. Seventeen patients with complete data underwent unsupervised clustering ( k ‐means) and principal component analysis (PCA) based on marker expression profiles. High GATA3 expression was strongly associated with worse prognosis (median OS: 8.6 months vs. 41.7 months, p = 0.00094). T‐bet and STAT3 expressions showed no significant individual association with survival. Clustering analysis revealed three distinct immunoprofiles: (1) low expression of all markers (intermediate survival, 28.1 months), (2) high STAT3 and T‐bet expressions with intermediate GATA3 expression (longest survival, 53.1 months), and (3) high GATA3 expression with low STAT3 and T‐bet expressions (poorest survival, 9.5 months). GATA3 is a robust prognostic marker in TMF, identifying patients with particularly poor outcomes. Its elevated expression delineates a Th2‐skewed, immunosuppressive phenotype that may inhibit Th1/Th17 pathways via transcriptional repression. Integrative profiling reveals immunobiological subgroups with divergent prognoses, supporting GATA3 as a potential tool for risk stratification and a candidate for targeted intervention in TMF.
- 18 December 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (2) , 304-308
Open AccessImmunoprofiling Reveals GATA3 as a Prognostic Marker in Transformed Mycosis Fungoides
Transformed mycosis fungoides (TMF) is a rare, aggressive variant of cutaneous T‐cell lymphoma characterized by the presence of large neoplastic cells and poor clinical outcomes. A retrospective cohort of 22 TMF patients was analyzed using immunohistochemistry on formalin‐fixed, paraffin‐embedded (FFPE) tissue for GATA3 ( n = 20), T‐bet ( n = 22), and STAT3 ( n = 22). Expression was quantified by image analysis integrated optical density per total area (IOD/area), standardized by z ‐score and correlated with survival. Seventeen patients with complete data underwent unsupervised clustering ( k ‐means) and principal component analysis (PCA) based on marker expression profiles. High GATA3 expression was strongly associated with worse prognosis (median OS: 8.6 months vs. 41.7 months, p = 0.00094). T‐bet and STAT3 expressions showed no significant individual association with survival. Clustering analysis revealed three distinct immunoprofiles: (1) low expression of all markers (intermediate survival, 28.1 months), (2) high STAT3 and T‐bet expressions with intermediate GATA3 expression (longest survival, 53.1 months), and (3) high GATA3 expression with low STAT3 and T‐bet expressions (poorest survival, 9.5 months). GATA3 is a robust prognostic marker in TMF, identifying patients with particularly poor outcomes. Its elevated expression delineates a Th2‐skewed, immunosuppressive phenotype that may inhibit Th1/Th17 pathways via transcriptional repression. Integrative profiling reveals immunobiological subgroups with divergent prognoses, supporting GATA3 as a potential tool for risk stratification and a candidate for targeted intervention in TMF.
- Open Access
- 1 January 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (1) , 135-139
Caso peculiar de doença linfoproliferativa afetando a pele e o colo uterino em homem transgênero
- 1 January 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (1) , 135-139
Open AccessCaso peculiar de doença linfoproliferativa afetando a pele e o colo uterino em homem transgênero
- Open Access
- 1 September 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (1) , 135-139
A unique case of a lymphoproliferative disorder affecting the skin and uterine cervix on a male transgender
- 1 September 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (1) , 135-139
Open AccessA unique case of a lymphoproliferative disorder affecting the skin and uterine cervix on a male transgender
A phase 2 study of first‐line nivolumab in patients with locally advanced or metastatic cutaneous squamous‐cell carcinoma
Background: Cutaneous squamous‐cell carcinoma (CSCC) is among the most frequent malignancies worldwide. For those not amenable to treatment with curative intent, immune checkpoint inhibition (ICI) with anti‐programmed death receptor 1 (PD‐1) antibodies has emerged as a novel therapeutic option. In this study, the authors sought to investigate the activity of the anti‐PD‐1 agent nivolumab in patients with advanced CSCC (aCSCC).Methods: CA209‐9JC was an open‐label, single‐arm, phase 2 study to evaluate the safety and/or efficacy of nivolumab in systemic treatment‐naive patients with aCSCC. Nivolumab (3 mg/kg) was administered every 2 weeks until disease progression, unacceptable toxicity, or 12 months of treatment. The primary end point was the best objective response rate (BORR) as per RECIST 1.1 criteria. Secondary end points included safety, progression‐free survival (PFS), and overall survival (OS).Results: Twenty‐four patients with aCSCC were enrolled with a median age of 74 years (range, 48–93). Among the 24 patients evaluable for response, the BORR was 58.3% (14/24); there were no complete responses. With a median follow‐up of 17.6 months, median duration of response has not been reached, and the estimated median PFS and OS were 12.7 and 20.7 months, respectively. Prior exposure to radiotherapy was associated with worse outcomes (p = .035, univariate analysis). Treatment‐related adverse events of any grade and grade ≥ 3 occurred in 21 (87.5%) and six (25%) patients, respectively, and one patient discontinued nivolumab due to toxicities.Conclusions: Nivolumab resulted in robust antitumor activity, sustained responses, and good tolerability in systemic treatment‐naive patients with aCSCC. These data provide further evidence to support the use of ICI as the standard treatment of aCSCC.
A phase 2 study of first‐line nivolumab in patients with locally advanced or metastatic cutaneous squamous‐cell carcinoma
Background: Cutaneous squamous‐cell carcinoma (CSCC) is among the most frequent malignancies worldwide. For those not amenable to treatment with curative intent, immune checkpoint inhibition (ICI) with anti‐programmed death receptor 1 (PD‐1) antibodies has emerged as a novel therapeutic option. In this study, the authors sought to investigate the activity of the anti‐PD‐1 agent nivolumab in patients with advanced CSCC (aCSCC).Methods: CA209‐9JC was an open‐label, single‐arm, phase 2 study to evaluate the safety and/or efficacy of nivolumab in systemic treatment‐naive patients with aCSCC. Nivolumab (3 mg/kg) was administered every 2 weeks until disease progression, unacceptable toxicity, or 12 months of treatment. The primary end point was the best objective response rate (BORR) as per RECIST 1.1 criteria. Secondary end points included safety, progression‐free survival (PFS), and overall survival (OS).Results: Twenty‐four patients with aCSCC were enrolled with a median age of 74 years (range, 48–93). Among the 24 patients evaluable for response, the BORR was 58.3% (14/24); there were no complete responses. With a median follow‐up of 17.6 months, median duration of response has not been reached, and the estimated median PFS and OS were 12.7 and 20.7 months, respectively. Prior exposure to radiotherapy was associated with worse outcomes (p = .035, univariate analysis). Treatment‐related adverse events of any grade and grade ≥ 3 occurred in 21 (87.5%) and six (25%) patients, respectively, and one patient discontinued nivolumab due to toxicities.Conclusions: Nivolumab resulted in robust antitumor activity, sustained responses, and good tolerability in systemic treatment‐naive patients with aCSCC. These data provide further evidence to support the use of ICI as the standard treatment of aCSCC.
- 7 June 2022
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 20 (7) , 1008-1010
Image‐guided lymph node core needle biopsy in mycosis fungoides/Sézary syndrome: Direct comparison to surgical excision
- 7 June 2022
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 20 (7) , 1008-1010
Image‐guided lymph node core needle biopsy in mycosis fungoides/Sézary syndrome: Direct comparison to surgical excision
- Open Access
- 26 November 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 97 (1) , 14-21
Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- 26 November 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 97 (1) , 14-21
Open AccessCutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Open Access
- 28 October 2021
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 4 (2) , e31838
From the Cochrane Library: Topical Tacrolimus for Atopic Dermatitis
- 28 October 2021
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 4 (2) , e31838
Open AccessFrom the Cochrane Library: Topical Tacrolimus for Atopic Dermatitis
- 4 September 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (6) , E213-E214
Use of hydrochlorothiazide and risk of nonmelanoma skin cancer: a pilot study in the Brazilian population
- 4 September 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (6) , E213-E214
Use of hydrochlorothiazide and risk of nonmelanoma skin cancer: a pilot study in the Brazilian population
- 1 September 2021
- Published by Elsevier in Annals of Oncology
- Vol. 32, S885
1064P Final results of CA209-9JC: A phase II study of first-line nivolumab in patients with advanced cutaneous squamous cell carcinoma
- 1 September 2021
- Published by Elsevier in Annals of Oncology
- Vol. 32, S885
1064P Final results of CA209-9JC: A phase II study of first-line nivolumab in patients with advanced cutaneous squamous cell carcinoma
- Open Access
- 6 July 2021
- Published by JMIR Publications Inc. in JMIR Preprints
From the Cochrane Library: Topical Tacrolimus for Atopic Dermatitis (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). ---
- 6 July 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessFrom the Cochrane Library: Topical Tacrolimus for Atopic Dermatitis (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). ---